Advertisement
Canada markets close in 6 hours 24 minutes
  • S&P/TSX

    21,597.88
    +10.00 (+0.05%)
     
  • S&P 500

    5,483.73
    +10.50 (+0.19%)
     
  • DOW

    38,847.44
    +69.34 (+0.18%)
     
  • CAD/USD

    0.7281
    -0.0008 (-0.11%)
     
  • CRUDE OIL

    80.60
    +0.27 (+0.34%)
     
  • Bitcoin CAD

    88,920.10
    -951.62 (-1.06%)
     
  • CMC Crypto 200

    1,351.83
    -37.58 (-2.70%)
     
  • GOLD FUTURES

    2,331.80
    +2.80 (+0.12%)
     
  • RUSSELL 2000

    2,022.01
    +15.85 (+0.79%)
     
  • 10-Yr Bond

    4.2500
    -0.0290 (-0.68%)
     
  • NASDAQ

    17,870.29
    +13.28 (+0.07%)
     
  • VOLATILITY

    12.62
    -0.13 (-1.02%)
     
  • FTSE

    8,187.32
    +45.17 (+0.55%)
     
  • NIKKEI 225

    38,482.11
    +379.67 (+1.00%)
     
  • CAD/EUR

    0.6781
    -0.0006 (-0.09%)
     

Teladoc (TDOC) Rises Yet Lags Behind Market: Some Facts Worth Knowing

Teladoc (TDOC) ended the recent trading session at $10.66, demonstrating a +0.19% swing from the preceding day's closing price. The stock's performance was behind the S&P 500's daily gain of 0.26%. Elsewhere, the Dow saw an upswing of 0.18%, while the tech-heavy Nasdaq appreciated by 0.35%.

Heading into today, shares of the telehealth services provider had lost 10.96% over the past month, lagging the Medical sector's gain of 3.06% and the S&P 500's gain of 3.25% in that time.

Analysts and investors alike will be keeping a close eye on the performance of Teladoc in its upcoming earnings disclosure. The company is expected to report EPS of -$0.35, up 12.5% from the prior-year quarter. At the same time, our most recent consensus estimate is projecting a revenue of $649.84 million, reflecting a 0.39% fall from the equivalent quarter last year.

TDOC's full-year Zacks Consensus Estimates are calling for earnings of -$1.05 per share and revenue of $2.65 billion. These results would represent year-over-year changes of +21.64% and +1.83%, respectively.

ADVERTISEMENT

Any recent changes to analyst estimates for Teladoc should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.

Our research shows that these estimate changes are directly correlated with near-term stock prices. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.

The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Within the past 30 days, our consensus EPS projection has moved 1.04% lower. Teladoc is currently a Zacks Rank #3 (Hold).

The Medical Services industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 91, positioning it in the top 37% of all 250+ industries.

The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Teladoc Health, Inc. (TDOC) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research